Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIS410 plus oseltamivir in hospitalized adults with influenza A requiring oxygen support
2016-004009-15Phase 2Completed
- Sponsor
- Visterra
- Start
- Jun 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of VIS410 in Influenza A infection (3 arms), sponsored by Visterra. Primary endpoint: Time to normalization of respiratory function. Started Jun 2017; status: completed.
02
Drugs
VIS410
03
Conditions
Influenza A infection
Beyond the preview
Go deeper on 2016-004009-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004009-15.